The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis

Experimental and Molecular Pathology

Volumn 91, Issue 3, 2011, Pages 718-722

  Jiménez Alvarez, Luis ^a   Arreola, José Luis ^a   Ramírez Martínez, Gustavo ^a   Ortiz Quintero, Blanca ^a   Gaxiola, Miguel ^a   Reynoso Robles, Rafael ^a   Avila Moreno, Federico ^a,c   Urrea, Francisco ^a   Pardo, Annie ^b   Selman, Moisés ^a   Zuñiga, Joaquín ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

CTLA 4Ig; Hypersensitivity pneumonitis; Lung inflammation; T cells

Indexed keywords

BELATACEPT;

ALLERGIC PNEUMONITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4 CD8 RATIO; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATORY CELL; LUNG INJURY; LUNG LAVAGE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANIMALS; ANTIGENS, CD28; B7 ANTIGENS; DISEASE PROGRESSION; FEMALE; IMMUNOCONJUGATES; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS;

MURINAE; MUS; SACCHAROPOLYSPORA;

EID: 80053531646     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.09.010     Document Type: Article

References (36)

1. Aujla S.J., Kolls J.K. IL-22: a critical mediator in mucosal host defense. J. Mol. Med. 2009, 87:451-454.
2. Barrera L., et al. Functional diversity of T cell subpopulations in subacute and chronic hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2008, 177:44-55.
3. Buch M.H., et al. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res. Ther. 2008, 10(Suppl. 1):S5.
4. Furlan R., et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55- induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 2003, 33:1830-1838.
5. Girard M., et al. Impaired function of regulatory T-cells in hypersensitivity pneumonitis. Eur. Respir. J. 2011, 37:632-639.
6. Hachem P., et al. Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFNgamma. Eur. J. Immunol. 2005, 35:2793-2802.
7. Hwang S.J., et al. IL-4-secreting NKT cells prevent hypersensitivity pneumonitis by suppressing IFN-gamma-producing neutrophils. J. Immunol. 2006, 177:5258-5268.
8. Irifune K., et al. T-helper 1 cells induce alveolitis but do not lead to pulmonary fibrosis in mice. Eur. Respir. J. 2003, 21:11-18.
9. Israël-Assayag E., et al. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis. J. Immunol. 1999, 163:6794-6799.
10. Jiménez-Alvarez L., et al. Inflammatory response and dynamics of lung T cell subsets in Th1, Th2 biased and Th2 deficient mice during the development of hypersensitivity pneumonitis. Exp. Mol. Pathol. 2010, 88:407-415.
11. Kremer J.M., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005, 52:2229-2232.
12. Lacasse Y., et al. HP study group: clinical diagnosis of hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2003, 168:952-958.
13. Linsley P.S., et al. Human B7-1(CD80) and B7-2(CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA4 receptors. Immunity 1994, 1:793-801.
14. Liu T.Y., et al. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur. J. Immunol. 2008, 38:1012-1023.
15. Mars L.T., et al. Invariant NKT cells inhibit development of the Th17 lineage. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6238-6243.
16. Mroz R.M., et al. Increased levels of Treg cells in bronchoalveolar lavage fluid and induced sputum of patients with active pulmonary sarcoidosis. Eur. J. Med. Res. 2009, 14:165-169.
17. Pardo A., et al. Bleomycin-induced pulmonary fibrosis is attenuated in gamma glutamyl transpeptidase-deficient mice. Am. J. Respir. Crit. Care Med. 2003, 167:925-932.
18. Park Y., et al. CD4(+)CD25(+) regulatory T cells attenuate hypersensitivity pneumonitis by suppressing IFN-gamma production by CD4(+) and CD8(+) T cells. J. Leukoc. Biol. 2009, 86:1427-1437.
19. Peach R.J., et al. Complementarity's determining region1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 1994, 180:2049-2058.
20. Ruderman E.M., Pope R.M. The evolving clinical profile of abatacept (CTLA-4Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 2005, 7(Suppl. 2):S21-S25.
21. Salomon B., Bluestone J.A. Complexities of CD28/27:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 2001, 19:225-252.
22. Schuyler M., et al. Experimental hypersensitivity pneumonitis: influence of Th2 bias. Int. J. Exp. Pathol. 1999, 80:335-348.
23. Selman M. Hypersensitivity pneumonitis: a multifaceted deceiving disorder. Clin. Chest Med. 2004, 25:531-547.
24. Selman M., et al. Hypersensitivity pneumonitis: clinical manifestations, diagnosis, pathogenesis and therapeutic strategies. Semin. Respir. Med. 1993, 14:353-359.
25. Simonian P., et al. Regulatory role of γδT cells in the recruitment of CD4+ and CD8+ T cells to lung and subsequent pulmonary fibrosis. J. Immunol. 2006, 177:4436-4443.
26. Simonian P.L., et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J. Immunol. 2009, 182:657-665.
27. Simonian P.L., et al. γδ T cells protect against lung fibrosis via IL-22. J. Exp. Med. 2010, 207:2239-2253.
28. Smolen J.S., et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874.
29. Uezu K., et al. Accumulation of γδ T cells in the lungs and their regulatory roles in Th1 response and host defense against pulmonary infection with Cryptococcus neoformans. J. Immunol. 2004, 172:7629-7634.
30. Viglietta V., et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008, 71:917-924.
31. Waldmann T.A. Effective cancer therapy through immunomodulation. Annu. Rev. Med. 2006, 57:65-81.
32. Walunas T.L., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
33. Walunas T.L., et al. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 1996, 183:2541-2550.
34. Westhovens R., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009, 68:1870-1877.
35. Witte E., et al. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010, 21:365-379.
36. Zachariadis O., et al. Gammadelta T cells regulate the early inflammatory response to bordetella pertussis infection in the murine respiratory tract. Infect. Immun. 2006, 74:1837-1845.